Actively Recruiting
ReneuRx Nerve Selective Therapy Compared to Corticosteroid Injection for Lateral Hip Pain A Multi-Center Randomized Controlled Trial
Led by Brixton Biosciences, Inc. · Updated on 2026-10-16
100
Participants Needed
11
Research Sites
104 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the safety and pain relief effects of the ReneuRx device compared to corticosteroid injections in adults aged 22 to 80 who suffer from moderate to severe chronic lateral hip pain associated with Greater Trochanteric Pain Syndrome. This trial aims to understand how the nerve selective therapy device performs against standard treatment in easing hip pain. The study is randomized and controlled, focusing on treatment outcomes and safety over time. Participants will be randomly assigned to receive either the ReneuRx device injection around the femoral nerve branches or a single corticosteroid injection consisting of 40mg Triamcinolone acetate mixed with saline. The treatment is administered once, and participants will be followed closely during the study period. The trial compares these two interventions in parallel groups to assess their analgesic performance and monitor any side effects. During the study, participants will attend scheduled visits and complete quality of life and pain questionnaires over a follow-up period of about 6 to 12 months. Researchers will measure primary effectiveness at 3 months post-treatment and continue to monitor safety for an average of 12 months. Various secondary effectiveness assessments will be conducted at multiple time points up to 12 months. This comprehensive monitoring includes patient-reported outcomes to understand improvements and any adverse events throughout the study.
CONDITIONS
Brief Title
ReneuRx™ (Nerve Selective Therapy) Utilized in Lateral Hip Pain
Research Team
D
David Curd
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here